Dr. Fenton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1030 Beaner Hollow Rd
Beaver, PA 15009Phone+1 724-774-0778
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2009 - 2012
Wayne State University School of MedicineResidency, Internal Medicine, 2006 - 2009
University of Tennessee Health Science Center College of MedicineClass of 2006
Certifications & Licensure
PA State Medical License 2009 - 2024
AR State Medical License 2012 - 2021
MS State Medical License 2012 - 2021
TN State Medical License 2012 - 2021- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
- Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Publications & Presentations
PubMed
- 78 citationsEffect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Rand...Robert L. Ferris, Nabil F. Saba, Barbara J. Gitlitz, Robert I. Haddad, Ammar Sukari
JAMA Oncology. 2018-11-01 - 384 citationsNCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018A. Dimitrios Colevas, Sue S. Yom, David G. Pfister, Sharon A. Spencer, David J. Adelstein
Journal of the National Comprehensive Cancer Network. 2018-05-01 - 172 citationsDurvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 express...Dan P. Zandberg, Alain Algazi, Antonio Jimeno, J. Good, Jérôme Fayette
European Journal of Cancer. 2019-01-01
Authored Content
- Patient Characteristics and Costs in Recurrent or Refractory Head and Neck Cancer: Retrospective Analysis of a Community Oncology DatabaseMarch 2018
Press Mentions
Head and Neck Cancers and the HPV ConnectionSeptember 2nd, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
